PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session

Survival rates for pancreatic cancer remain dismal. Current standard of care treatment regimens provide transient clinical benefit but eventually chemoresistance develops. Tumors deficient in deoxyribonucleic acid (DNA) damage repair mechanisms such as BRCA mutants show better responses to platinum...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Rajvi, Fein, Daniel, Ramirez, Carolina B., Do, Kevin, Saif, Muhammad W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003614/
https://www.ncbi.nlm.nih.gov/pubmed/32030362
http://dx.doi.org/10.17140/POJ-3-e011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003614/
https://www.ncbi.nlm.nih.gov/pubmed/32030362
http://dx.doi.org/10.17140/POJ-3-e011

Ejemplares similares